Table 2.
Relationship of time-varying change in lipoprotein(a) with subsequent incident type 2 diabetes in the alirocumab group
| Model | Model adjustments | HR (95% CI) per 10 mg/dL decrease in lipoprotein(a) from baseline | P |
|---|---|---|---|
| 1 | None | 1.07 (1.03−1.12) | 0.0002 |
| 2 | Baseline lipoprotein(a) | 1.10 (1.05−1.15) | <0.0001 |
| 3 | Baseline lipoprotein(a), baseline LDL-Ccorrected, time-varying change in LDL-Ccorrected, demographic and clinical characteristics* | 1.08 (1.04−1.13) | 0.0001 |
HR, hazard ratio for incident type 2 diabetes; LDL-Ccorrected, LDL cholesterol corrected for cholesterol content of lipoprotein(a).
*
Sex, race, geographic region, statin treatment intensity (none, low to moderate, or high), baseline BMI, baseline triglycerides, baseline hemoglobin A1c.